Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.

ABSTRACT:

Background

Serum thymidine kinase 1 (sTK1) activity is closely correlated with DNA synthesis.

Objectives

Evaluate sTK1 activity as a biomarker for treatment response and early detection of relapse in dogs with lymphoma.

Animals

Ninety-seven client-owned dogs with naive or relapsed lymphoma and 23 healthy dogs.

Methods

Prospective study. Serum TK1 activity measured by refined ELISA-based method (DiviTum assay, Biovica International) before treatment, at clinical response, and every 4 weeks until relapse or last follow-up.

Results

Serum TK1 activity was ≤20 Du/L in 96% (22/23) of healthy dogs. Pretreatment sTK1 activity was >20 Du/L in 88% (85/97) dogs with lymphoma. At clinical response, sTK1 activity was significantly lower in dogs with complete (CR, n =

SUBMITTER: Boye P 

PROVIDER: S-EPMC6639481 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature